FLNA
Filana Therapeutics Inc. · NASDAQ
- Market cap
- $21.5M
Filana Therapeutics Inc. (FLNA) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 9 wire items for FLNA, including 4 SEC filings, 2 insider trades and 1 press release or news item. The most recent was published Nov 12, 2026.
Financial highlights
Full financials- Net income, TTM
- -$42.20M
- Cash
- $46.99M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks19+100%
2026-05-242026-11-15
Mix1590d
- SEC Filings6(40%)
- Insider4(27%)
- Other3(20%)
- Earnings1(7%)
- Leadership1(7%)
Activity · 52 weeks2717 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- INSIDERDirector Quigley Jill M. was granted 53,000 stock options (SEC Form 4)4 - FILANA THERAPEUTICS, INC. (0001069530) (Issuer)
- INSIDERSEC Form 3 filed by new insider Quigley Jill M.3 - FILANA THERAPEUTICS, INC. (0001069530) (Issuer)
- SECFilana Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - FILANA THERAPEUTICS, INC. (0001069530) (Filer)
- PRFilana Therapeutics Names Biopharma Executive Jill M. Quigley to BoardAUSTIN, Texas, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ:FLNA), a biotechnology company focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced the appointment of Jill M. Quigley to its Board of Directors (the "Board"). Ms. Quigley brings additional executive leadership experience to Filana, having previously scaled biopharma companies through pivotal stages of drug development, financing, and value creation. "On behalf of the Board, I welcome Jill to Filana. Her record of guiding companies through financings and strategic growth will broaden the expertise around our Board table," commented Claude Nicaise, MD, Chairm
- SECSEC Form 10-Q filed by Filana Therapeutics Inc.10-Q - FILANA THERAPEUTICS, INC. (0001069530) (Filer)
- SECFilana Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - FILANA THERAPEUTICS, INC. (0001069530) (Filer)
- PRFilana Therapeutics Reports Q3 2026 Financial Results and Provides Business Update– Patient screening in Phase 2a study of simufilam in TSC-related epilepsy expected to begin by Q1 2027, following recent lift of FDA clinical hold – Recent publication in Cells1 provides new insights into simufilam’s potential mechanism of action AUSTIN, Texas, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ:FLNA, "Filana Therapeutics", the "Company")) today reported financial results for the third quarter ended September 30, 2026. "Simufilam has the potential to make a meaningful difference for patients with TSC-related epilepsy. We began working toward activating clinical study sites as soon as FDA lifted the clinical hold in September. Patient screening is expec
- PRFilana Therapeutics Announces Publication in Cells of Promising Preclinical Findings for Simufilam in TSC2-Deficient CellsFindings provide new insight into simufilam’s effects on cellular stress responses and mitochondrial function New research demonstrates a 37% reduction in elevated ATF4, consistent with attenuation of the ATF4-associated cellular stress response Patient screening for planned Phase 2a study expected to begin by first quarter of 2027 AUSTIN, Texas, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ:FLNA, "Filana Therapeutics", the "Company")), a biotechnology company currently focused on developing simufilam for the treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced the publication by Yale researchers of new preclinical research on simuf
- SECSEC Form 8-K filed by Filana Therapeutics Inc.8-K - FILANA THERAPEUTICS, INC. (0001069530) (Filer)
- PRFilana Therapeutics to Participate in the 2026 Maxim Growth SummitAUSTIN, Texas, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ:FLNA, ", Filana Therapeutics", , the ", Company", )), a biotechnology company currently focused on developing therapies for the treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that the Company’s management team will participate in the 2026 Maxim Growth Summit being held October 12-14, 2026 in New York. 2026 Maxim Growth Summit Conference Details: Format: One-on-one meetingsDate: October 12–14, 2026Location: The Hard Rock Hotel NYC For more information and a complete agenda, please visit www.maximgrp.com/2026-growth-summit. About Filana Therapeutics, Inc. Filana Therapeut
- INSIDERPresident & CEO Barry Richard bought $278,132 worth of shares (306,813 units at $0.91) (SEC Form 4)4 - FILANA THERAPEUTICS, INC. (0001069530) (Issuer)
- INSIDERPresident & CEO Barry Richard bought $78,196 worth of shares (93,091 units at $0.84) (SEC Form 4)4 - FILANA THERAPEUTICS, INC. (0001069530) (Issuer)
- SECFilana Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - FILANA THERAPEUTICS, INC. (0001069530) (Filer)
- PRFilana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related EpilepsyPatient screening for the Phase 2a study is expected to begin by the first quarter of 2027Filana has engaged a leading clinical research organization, has identified clinical trial sites, and is recruiting potential investigatorsOngoing collaboration with the TSC Alliance and the broader TSC community is intended to support patient engagement and study execution AUSTIN, Texas, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ:FLNA, "Filana Therapeutics", the "Company")), a biotechnology company currently focused on developing simufilam for the treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that the U.S. Food and Drug Administration (FDA)
- SECFilana Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - FILANA THERAPEUTICS, INC. (0001069530) (Filer)
- SECSEC Form 10-Q filed by Filana Therapeutics Inc.10-Q - FILANA THERAPEUTICS, INC. (0001069530) (Filer)
- SECFilana Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - FILANA THERAPEUTICS, INC. (0001069530) (Filer)
- PRFilana Therapeutics Reports Q2 2026 Financial Results and Provides Business UpdateAUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ:FLNA, "Filana Therapeutics", the "Company")), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the second quarter ended June 30, 2026 and provided a business update. "The Company continues to engage with the FDA regarding the clinical hold on its proof-of-concept trial in TSC-related epilepsy. The Company is working diligently to address the FDA’s request for information in order to have the clinical hold lifted," said Rick Barry, President and Chief Executive Officer of Filana Therapeutics, Inc. "In
- SECFilana Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders8-K - FILANA THERAPEUTICS, INC. (0001069530) (Filer)
- SECSEC Form 10-Q filed by Filana Therapeutics Inc.10-Q - FILANA THERAPEUTICS, INC. (0001069530) (Filer)
- SECFilana Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - FILANA THERAPEUTICS, INC. (0001069530) (Filer)
- PRFilana Therapeutics Reports Q1 2026 Financial Results and Business UpdateAUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ:FLNA, "Filana Therapeutics", the "Company")), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the first quarter ended March 31, 2026 and provided a business update on the development of simufilam, an oral small molecule intended to modulate filamin A protein. "2026 has been a year of important progress and new beginnings for Filana Therapeutics. Our new name reflects who we are—a team dedicated to rigorous science and to bringing new treatment options to patients with TSC-related epilepsy and their f
- PRFilana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIIIAUSTIN, Texas, May 05, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ:FLNA, "Filana Therapeutics", the "Company")), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that it delivered a scientific presentation at Eilat XVIII (the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices) in Madrid, Spain. The presentation outlined the biological rationale underlying the Company's clinical development program evaluating simufilam in TSC-related epilepsy. "We are pleased to engage with the epilepsy community at this important international meeting. This gathering has provided the op
- SECSEC Form DEF 14A filed by Filana Therapeutics Inc.DEF 14A - FILANA THERAPEUTICS, INC. (0001069530) (Filer)
- SECSEC Form 8-K filed by Filana Therapeutics Inc.8-K - FILANA THERAPEUTICS, INC. (0001069530) (Filer)
FLNA FAQ
7 questionsWhat is the latest news on FLNA?
In the last 30 days Quantisnow tracked 9 wire items for FLNA: 4 SEC filings, 2 insider trades, 1 press release or news item and 1 earnings update. The most recent was published on November 12, 2026.Is FLNA profitable?
No. Filana Therapeutics Inc. reported a net loss of $42.20M for the twelve months ended Sep 30, 2026.How much cash and debt does FLNA have?
Filana Therapeutics Inc. reported $46.99M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does FLNA stock trade?
Filana Therapeutics Inc. (FLNA) is listed on NASDAQ.What sector and industry is FLNA in?
Filana Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What companies are similar to FLNA?
Notable peers in the same industry include MRK (Merck & Company Inc.), NVO (Novo Nordisk A/S), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories). Compare FLNA side-by-side with any of them on Quantisnow.How can I track FLNA on Quantisnow?
Quantisnow aggregates Filana Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow FLNA to receive live email and push alerts on every new disclosure.